Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study.
atrial fibrillation
cancer
nationwide study
neoplasms
prevalence
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
19
08
2022
revised:
17
11
2022
accepted:
23
11
2022
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
10
3
2023
Statut:
epublish
Résumé
Atrial fibrillation (AF) is an increasingly recognized codiagnosis in patients with cancer. This study aimed to provide a robust and contemporary estimate on the coprevalence and relative risk of AF in patients with cancer. We conducted a nationwide analysis, utilizing diagnosis codes from the Austrian Association of Social Security Providers dataset. Estimates of the coprevalence of cancer and AF and the relative risk of AF in patients with cancer compared with individuals without cancer were obtained as point prevalences with binomial exact confidence intervals and summarized across age groups and cancer types with random-effects models. Overall, 8,306,244 persons were included in the present analysis, of whom 158,675 (prevalence estimate, 1.91%; 95% CI, 1.90-1.92) had a cancer diagnosis code and 112,827 (1.36%; 95% CI, 1.35-1.36) an AF diagnosis code, respectively. The prevalence estimate for AF in patients with cancer was 9.77% (95% CI, 9.63-9.92) and 1.19% (95% CI, 1.19-1.20) in the noncancer population. Conversely, 13.74% (95% CI, 13.54-13.94) of patients with AF had a concurrent cancer diagnosis. The corresponding age-stratified random-effects relative risk ratio for AF in patients with cancer compared with no cancer diagnosis was 10.45 (95% CI, 7.47-14.62). The strongest associations between cancer and AF were observed in younger persons and patients with hematologic malignancies. Cancer and AF have a substantial coprevalence in the population. This finding corroborates the concept that cancer and AF have common risk factors and pathophysiology.
Sections du résumé
Background
UNASSIGNED
Atrial fibrillation (AF) is an increasingly recognized codiagnosis in patients with cancer.
Objectives
UNASSIGNED
This study aimed to provide a robust and contemporary estimate on the coprevalence and relative risk of AF in patients with cancer.
Methods
UNASSIGNED
We conducted a nationwide analysis, utilizing diagnosis codes from the Austrian Association of Social Security Providers dataset. Estimates of the coprevalence of cancer and AF and the relative risk of AF in patients with cancer compared with individuals without cancer were obtained as point prevalences with binomial exact confidence intervals and summarized across age groups and cancer types with random-effects models.
Results
UNASSIGNED
Overall, 8,306,244 persons were included in the present analysis, of whom 158,675 (prevalence estimate, 1.91%; 95% CI, 1.90-1.92) had a cancer diagnosis code and 112,827 (1.36%; 95% CI, 1.35-1.36) an AF diagnosis code, respectively. The prevalence estimate for AF in patients with cancer was 9.77% (95% CI, 9.63-9.92) and 1.19% (95% CI, 1.19-1.20) in the noncancer population. Conversely, 13.74% (95% CI, 13.54-13.94) of patients with AF had a concurrent cancer diagnosis. The corresponding age-stratified random-effects relative risk ratio for AF in patients with cancer compared with no cancer diagnosis was 10.45 (95% CI, 7.47-14.62). The strongest associations between cancer and AF were observed in younger persons and patients with hematologic malignancies.
Conclusion
UNASSIGNED
Cancer and AF have a substantial coprevalence in the population. This finding corroborates the concept that cancer and AF have common risk factors and pathophysiology.
Identifiants
pubmed: 36891526
doi: 10.1016/j.rpth.2022.100026
pii: S2475-0379(22)02277-4
pmc: PMC9986100
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100026Informations de copyright
© 2022 The Author(s).
Références
Cardiol Res Pract. 2019 Apr 14;2019:8985273
pubmed: 31110819
J Clin Oncol. 2010 Nov 20;28(33):4898-905
pubmed: 20940190
Arch Intern Med. 1995 Mar 13;155(5):469-73
pubmed: 7864703
Europace. 2020 Jan 1;22(1):58-65
pubmed: 31750897
Pharmacol Ther. 2018 Sep;189:89-103
pubmed: 29698683
PLoS One. 2018 Oct 5;13(10):e0205454
pubmed: 30289944
J Arrhythm. 2018 Jun 04;34(4):394-401
pubmed: 30167010
Am J Cardiol. 2013 Oct 15;112(8):1142-7
pubmed: 23831166
Can J Cardiol. 2019 Nov;35(11):1449-1456
pubmed: 31679617
Intern Emerg Med. 2008 Sep;3(3):227-31
pubmed: 18320149
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Drugs. 2012 Aug 20;72(12):1617-30
pubmed: 22834678
Nat Rev Clin Oncol. 2015 Oct;12(10):584-96
pubmed: 26122183
PLoS One. 2014 Aug 13;9(8):e102861
pubmed: 25119880
J Am Coll Cardiol. 2012 Dec 4;60(22):2263-70
pubmed: 23194937
Ann Thorac Surg. 2010 Aug;90(2):368-74
pubmed: 20667313
J Cardiothorac Surg. 2012 Jan 10;7:4
pubmed: 22233837
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
Circ Arrhythm Electrophysiol. 2008 Apr;1(1):62-73
pubmed: 19808395
Eur Heart J. 2013 Apr;34(15):1102-11
pubmed: 22789916
Eur Heart J. 2013 Sep;34(35):2746-51
pubmed: 23900699
Nature. 2016 Jan 7;529(7584):43-7
pubmed: 26675728
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Front Pharmacol. 2018 Oct 16;9:1058
pubmed: 30386232
JAMA Cardiol. 2016 Jul 1;1(4):389-96
pubmed: 27438314
Br J Cancer. 2011 Sep 27;105(7):881-3
pubmed: 21878939
J Oncol Pract. 2019 Dec;15(12):641-650
pubmed: 31825754
J Thorac Cardiovasc Surg. 2005 Aug;130(2):438-44
pubmed: 16077410
Int J Cardiol. 2013 May 10;165(2):355-7
pubmed: 22989607
Eur Heart J Qual Care Clin Outcomes. 2017 Jul 1;3(3):192-197
pubmed: 28838088
Ann Surg. 2014 Nov;260(5):772-8; discussion 778
pubmed: 25379848
Circulation. 2017 Aug 8;136(6):583-596
pubmed: 28784826
Surg Today. 2017 Feb;47(2):252-258
pubmed: 27382978
J Thromb Haemost. 2019 Aug;17(8):1247-1252
pubmed: 31207027
N Engl J Med. 2019 Oct 3;381(14):1378-1386
pubmed: 31577882
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Eur Heart J. 2006 Apr;27(8):949-53
pubmed: 16527828
BMC Cancer. 2019 Nov 14;19(1):1105
pubmed: 31726997
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154
Pacing Clin Electrophysiol. 2005 Jan;28 Suppl 1:S120-3
pubmed: 15683477
J Am Coll Cardiol. 2014 Mar 18;63(10):945-53
pubmed: 24361314
J Am Coll Cardiol. 2019 Mar 26;73(11):1336-1349
pubmed: 30898209
Intern Emerg Med. 2012 Oct;7(5):431-8
pubmed: 21968511
Thromb Haemost. 2020 Feb;120(2):314-321
pubmed: 31785599